My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Biogen Idec (NQ:BIIB)

181.65 +0.90 (+0.50%)

Streaming Delayed Price Updated: 3:53 PM EST, Dec 4, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

56 57 Next >

The 7 Hottest Healthcare Stocks to Own for 2023 and Beyond ↗

December 18, 2022

These seven hottest healthcare stocks have strong growth catalysts that could send each of them higher over the next few years.

Via InvestorPlace

Buying These Unstoppable Stocks Before 2023 Could Be a Genius Move ↗

December 18, 2022

These stocks have climbed by double digits this year.

Via The Motley Fool

Better Bear Market Buy: Vertex Pharmaceuticals vs. Biogen Stock ↗

December 18, 2022

Both stocks are heading for double-digit gains this year.

Via The Motley Fool

FDA Accepts Biogen Biologics License Application for BIIB800, A Biosimilar Candidate Referencing ACTEMRA® (tocilizumab)

December 09, 2022

From Biogen Inc.

Via GlobeNewswire

3 Revolutionary Stocks I'd Buy Right Now Without Hesitation ↗

December 08, 2022

The three companies are changing the pharmaceutical industry.

Via The Motley Fool

Is Biogen Stock a Buy Now? ↗

December 04, 2022

Its revenue now has a plausible path to doubling, but risks remain high.

Via The Motley Fool

CrowdStrike (CRWD) Stock Sinks on Weak Guidance ↗

November 30, 2022

CrowdStrike (CRWD) stock is falling on Wednesday following the release of its earnings report for the third quarter of 2022.

Via InvestorPlace

Why 2023 Could Be a Big Year for Biogen ↗

December 07, 2022

Investors will soon learn if the company's Alzheimer's treatment gets the green light.

Via The Motley Fool

Sage Therapeutics and Biogen Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

December 06, 2022

From Sage Therapeutics, Inc.

Via Business Wire

European Medicines Agency Accepts Tofersen Marketing Authorization Application to Treat Rare, Genetic Form of ALS

December 05, 2022

From Biogen Inc.

Via GlobeNewswire

26 Analysts Have This to Say About Biogen ↗

November 30, 2022

Via Benzinga

Even After This Year’s Melt-Up, Runway Remains for LLY Stock ↗

December 05, 2022

The market hasn't overreacted with its enthusiasm for LLY stock, as the pharma giant makes progress with a blockbuster drug in the making.

Via InvestorPlace

Can These 2 Stocks Crush the Market Again in 2023? ↗

December 04, 2022

Both are riding the wave of major clinical wins

Via The Motley Fool

Stock Market Rally Fights At Key Level On Powell, Inflation Data, Jobs Report: Weekly Review ↗

December 02, 2022

The S&P 500 is fighting for its 200-day, a critical level for the uptrend.

Via Investor's Business Daily

Despite Safety Concerns, Analysts Are Bullish On Biogen's Second Alzheimer's Candidate ↗

November 30, 2022

Eisai Limited (OTC: ESALY) and partner Biogen Inc (NASDAQ: BIIB) presented detailed data from the positive Phase 3 CLARITY-AD study of lecanemab in early Alzheimer's disease (AD).

Via Benzinga

BIIB Stock Alert: What the Latest Alzheimer’s Drug Data Means for Biogen ↗

November 30, 2022

Biogen (BIIB) stock is on the move Wednesday after the company provided the latest update on its Alzheimer's drug candidate.

Via InvestorPlace

Open Questions On Safety Lingers After Eisai-Biogen's Detailed Lecanemab Data For Alzheimer's ↗

November 30, 2022

Via Benzinga

Biogen Stock Is Surging Today: What's Going On? ↗

November 30, 2022

Biogen Inc (NASDAQ: BIIB) shares are trading higher Wednesday after the company announced positive trial results for its experimental Alzheimer's

Via Benzinga

Alphabet To $135? Here Are 10 Other Price Target Changes For Wednesday ↗

November 30, 2022

Mizuho cut Alphabet Inc. (NASDAQ: GOOGL) price target from $140 to $135. Mizuho analyst James Lee maintained a Buy rating on the stock. Alphabet shares gained 0.4% to $95.53 in pre-market trading.

Via Benzinga

Why This New Alzheimer's Update Is Likely To Spark A Debate For Biogen Investors ↗

November 29, 2022

The update from Eisai suggests there is a benefit question ahead of the companies.

Via Investor's Business Daily

10 Health Care Stocks Whale Activity In Today's Session ↗

November 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Biogen Dives On Reports Of Alzheimer's Death While Axsome Soars On Its Study Success ↗

November 28, 2022

Biogen and Axsome stocks diverged Monday on news out of their Alzheimer's studies.

Via Investor's Business Daily

Biogen's Potential Early Alzheimer's Treatment Sees Second Death Linked To It, Shares Fall ↗

November 28, 2022

A 65-year-old woman with early Alzheimer's disease receiving Biogen Inc's (NASDAQ: BIIB) antibody lecanemab treatment to slow the cognitive decline recently died from a massive brain hemorrhage that...

Via Benzinga

Market Currents: Why Pick Stocks? ↗

November 28, 2022

Effective investing is changing. You can no longer just buy the S&P 500 and be done. Going forward you have to have a strategy and stock picking will become much more essential. Steve Brennan and...

Via Talk Markets

2 Stocks Near 52-Week Highs That Could Climb Higher ↗

November 28, 2022

This pair of stocks are bucking the trend and they could climb even higher.

Via The Motley Fool

CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention

November 23, 2022

The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400.

Via TheNewswire.com

Topics ETFs Economy Stocks

CBOE's Weekly Market Recap: Nov.14-18 – Biogen’s Alzheimer’s Drug Captures Investors’ Attention

November 23, 2022

By Jad Malaeb, Benzinga

Via News Direct

Topics ETFs Economy

How to Trade the High-Growth Biotech Sector in the Midst of a Bear Market ↗

November 23, 2022

Biotech is an exciting and emerging space that’s attracted increasing investor interest in recent years.

Via Benzinga

CBOE's Weekly Market Recap: Nov.14-18 – Biogen's Alzheimer's Drug Captures Investors' Attention ↗

November 23, 2022

The market has experienced some relief from bearish price action in November, continuing October’s push to usher the SPDR S&P 500 ETF (NYSEARCA: SPY) toward $400.

Via Benzinga

Not All Offices Are Created Equal… You Can Profit From One Sector That’s Poised to See Demand Growth ↗

November 22, 2022

Despite what we might see in the upcoming year with office real estate or specific companies within the life sciences industry, REITs with exposure to in-demand properties remain a great way to earn...

Via Talk Markets

< Previous 1 2

...

27 28 29 30 31 32 33 34 35

...

56 57 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.